MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation) + MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation) + MenACWY PS (MenACWY-CRM, polysaccharide vaccine) + HBV (Hepatitis B vaccine) + Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197) + MMR (Measles, Mumps and Rubella vaccine) + DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine) + Menjugate (Men C conjugated vaccine)
Phase 2CompletedDevelopment Stage
Prevention of Meningococcal Disease
Prevention of Meningococcal Disease
Sep 1, 2004 → Oct 1, 2006
About MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation) + MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation) + MenACWY PS (MenACWY-CRM, polysaccharide vaccine) + HBV (Hepatitis B vaccine) + Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197) + MMR (Measles, Mumps and Rubella vaccine) + DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine) + Menjugate (Men C conjugated vaccine)
MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation) + MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation) + MenACWY PS (MenACWY-CRM, polysaccharide vaccine) + HBV (Hepatitis B vaccine) + Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197) + MMR (Measles, Mumps and Rubella vaccine) + DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine) + Menjugate (Men C conjugated vaccine) is a phase 2 stage product being developed by Novartis for Prevention of Meningococcal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00262002. Target conditions include Prevention of Meningococcal Disease.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00262002 | Phase 2 | Completed |
Competing Products
20 competing products in Prevention of Meningococcal Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| edoxaban + enoxaparin sodium | Daiichi Sankyo | Phase 3 | 77 |
| Mifepristone | Eli Lilly | Phase 2 | 52 |
| EXANTA | AstraZeneca | Phase 2 | 52 |
| Risk of low dose aspirin discontinuation | AstraZeneca | Pre-clinical | 23 |
| DAPA/MET XR + DAPA + MET XR | AstraZeneca | Phase 3 | 77 |
| Esomeprazole + Placebo | AstraZeneca | Phase 3 | 77 |
| PCV15 | Merck | Pre-clinical | 23 |
| Raltegravir | Merck | Approved | 85 |
| RotaTeq (V260) + IPV | Merck | Phase 3 | 77 |
| V501 | Merck | Phase 3 | 77 |
| Zostavax | Merck | Phase 3 | 77 |
| V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920 | Merck | Phase 3 | 77 |
| Letermovir + Placebo | Merck | Phase 3 | 77 |
| Meningococcal C conjugate vaccine | Novartis | Approved | 85 |
| Enteric-coated mycophenolate sodium | Novartis | Phase 3 | 77 |
| Meningococcal C conjugate vaccine | Novartis | Approved | 85 |
| rMenB+OMV NZ | Novartis | Phase 3 | 77 |
| Enteric-Coated Mycophenolate Sodium | Novartis | Phase 3 | 77 |
| Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5ml | Novartis | Phase 3 | 77 |
| Meningococcal C Conjugate Vaccine | Novartis | Phase 3 | 77 |